To investigate the immunogenicity and protective efficacy of cold-adapted influenza vaccine in individuals with underlying immunity to influenza A virus, we administered cold-adapted HlNl and H3N2 vaccines to adults with prevaccination serum hemagglutination inhibition antibody titers of 1:16 or more and challenged them 1 month afterwards with homologous wild-type influenza A virus. Both cold-adapted vaccines were immunogenic in seropositive adults. In addition, individuals receiving cold-adapted vaccines had lower rates of virus shedding and illness following challenge with wild-type influenza virus than did unvaccinated seropositive volunteers.
Cold-adapted influenza A viruses generated by genetic reassortment between a wild-type influenza A virus and the cold-adapted influenza A/Ann Arbor/6/60 virus are currently being evaluated as live attenuated influenza A vaccines. Such vaccines are safe and immunogenic in seronegative children and young adults (1, 2, 5, 7, 9, 10, 12, 15) and induce resistance to challenge with homologous wild-type influenza A viruses in such individuals at least equal to that induced by currently available inactivated influenza vaccines (3, 4). Individuals with various levels of preexisting immunity to influenza A virus will ultimately need to be included in any strategy to use these vaccines, but the presence of antibodies induced by prior natural infection with influenza A virus may dampen the immune response to the cold-adapted virus vaccine (6, 8) . To determine the extent to which prior natural immunity might influence the immunogenicity of attenuated influenza A virus vaccines, we administered H3N2 and HlNi cold-adapted reassortant influenza A viruses to adults with serum hemagglutination inhibition (HI) antibody titers of 1:16 or more and measured their immune responses and subsequent resistance to challenge with homologous wildtype influenza A virus.
The wild-type and cold-adapted influenza A/California/10/ 78 (HlNi) and A/Bethesda/1/85 (H3N2) viruses used in this study were obtained from Flow Laboratories, Inc., McLean, Va. These viruses were cloned and safety tested as described previously (12, 13 (12 Serum and nasal wash specimens collected prior to and 1 month after vaccination and a third serum sample collected 1 month after challenge were used for the determination of immunoglobulin G (IgG) and IgA antibody responses to the viral HA by HI and an enzyme immunoassay (EIA) (11) . The EIA was performed as previously described for the determination of IgG responses to the influenza virus HA (11 units was considered significant after preliminary experiments determined that this value was greater than 2 standard deviations from that obtained after 15 determinations on four samples representing initial optical density values from 0.10 to 1.50 for each HA antigen used.
Volunteers were examined twice daily for 7 days following challenge with wild-type influenza A virus (14) . Volunteers experiencing cough, sore throat, stuffy nose, or myalgia on two or more occasions were considered ill. Individuals with an oral temperature of -38°C were considered febrile, and individuals with fever were also considered ill. Nasal wash specimens for isolation and titration of influenza A virus were obtained prior to challenge and daily for 7 days afterward and inoculated freshly onto Madin-Darby canine kidney (MDCK) cells. The titer of virus in samples from which virus was recovered was determined by standard methods.
The humoral immune response of seropositive volunteers to immunization with cold-adapted HlNl and H3N2 virus vaccines and inactivated trivalent vaccine is shown in The response of those challenged with the A/Bethesda/85 (H3N2) wild-type virus is also shown in Table 2 . All of the seronegative volunteers were infected by the wild-type virus, and 80% shed detectable virus in their nasal secretions in moderate levels. In addition, two of five of these volunteers experienced mild influenzalike symptoms following challenge, similar to the response seen in previous studies (13 positive adults with the cold-adapted influenza viruses in this study was an increase in nasal secretion HA IgA. The rates of immune response to the cold-adapted A/ Bethesda/85 (H3N2) vaccine in this study were comparable to those seen previously when the cold-adapted A/Washington/80 (H3N2) vaccine was administered to seropositive volunteers (6) . In that study, 33% of young adults with preimmunization serum HI titers of 1:8 or more had a nasal HA IgA antibody response, and 71% achieved a postvaccination nasal HA IgA titer of 1:64 or greater (6) . A somewhat higher rate of nasal IgA response was seen following the H3N2 vaccine in the current study, but the ultimate titer achieved was slightly lower. These differences could conceivably be accounted for by differences in the techniques used for measurement of antibody in the two studies.
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